Home Cart Sign in  
Chemical Structure| 2189684-44-2 Chemical Structure| 2189684-44-2

Structure of Lenacapavir
CAS No.: 2189684-44-2

Chemical Structure| 2189684-44-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lenacapavir is a novel HIV-1 capsid inhibitor that effectively suppresses HIV virus replication, serving as an important tool in HIV infection treatment research.

Synonyms: GS-6207

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lenacapavir

CAS No. :2189684-44-2
Formula : C39H32ClF10N7O5S2
M.W : 968.28
SMILES Code : FC(F)(F)CN(N=C1NS(C)(=O)=O)C2=C1C(Cl)=CC=C2C3=CC=C(C#CC(C)(S(C)(=O)=O)C)N=C3[C@H](CC4=CC(F)=CC(F)=C4)NC(CN5N=C(C(F)(F)F)C6=C5C(F)(F)[C@H]7[C@@H]6C7)=O
Synonyms :
GS-6207
MDL No. :N/A

Safety of Lenacapavir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Target
  • HIV-1 caspid

    HIV-1 capsid, EC50:0.1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
human PBMCs 122 pM 7 days Evaluate the inhibitory effect of Lenacapavir on stHIV-A19 in human PBMCs PMC10470178
TZM-bl cells 60 pM 48 h Determine antiviral potency of LEN at the lowest p24 levels, EC50 was 60 pM PMC11892807
pigtail macaque PBMCs 149 pM 7 days Evaluate the inhibitory effect of Lenacapavir on stHIV-A19 in pigtail macaque PBMCs PMC10470178
SupT1-CCR5 cells 91 pM 7 days Evaluate the inhibitory effect of Lenacapavir on stHIV-A19, showing comparable efficacy to HIV-1 NL4-3 PMC10470178
rhesus PBMCs 0.39 nM (EC50), 0.91 nM (EC95) 7 days To evaluate the in vitro antiviral activity of Lenacapavir against SHIV, showing potent inhibition. PMC10425210
Jurkat/Vpr-HiBiT T cells 5 μM 3 days Screened compounds inhibiting HIV-1 release, identified 10 candidate compounds PMC11419809

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Pigtail macaques StHIV-A19 infection model Subcutaneous injection 25 mg/kg Single injection, virus challenge after 30 days Evaluate the preventive effect of Lenacapavir against stHIV-A19 in pigtail macaques, showing all treated animals were protected from infection PMC10470178
Rhesus macaques SHIV rectal challenge model Subcutaneous injection 5-75 mg/kg Single dose, monitored up to 25 weeks To evaluate the pharmacokinetic profile and prophylactic efficacy of Lenacapavir in rhesus macaques. Results showed long plasma half-life and complete protection against SHIV infection when plasma drug concentrations exceeded 70 nM. PMC10425210

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.03mL

0.21mL

0.10mL

5.16mL

1.03mL

0.52mL

10.33mL

2.07mL

1.03mL

 

Historical Records

Categories